Vejle Hospital
π©π°Denmark
- Country
- π©π°Denmark
- Ownership
- Private
- Established
- 1890-01-01
- Employees
- -
- Market Cap
- -
ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT01481194
- Locations
- π©π°
Department of Hematology, Vejle, Denmark
A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2014-12-04
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 49
- Registration Number
- NCT01472770
- Locations
- π©π°
Department of Oncology, Vejle Hospital, Vejle, Denmark
Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 49
- Registration Number
- NCT01472783
- Locations
- π©π°
Department of Oncology, Vejle Hospital, Vejle, Denmark
Ceramic-on-Ceramic Total Hip Arthroplasty and Squeaking: Influence of Component Design
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 204
- Registration Number
- NCT01420900
- Locations
- π©π°
Department of Orthopedic Surgery, Vejle Hospital, Vejle, Denmark
Ultrasound Elastography in Patients With Rectal Cancer
- First Posted Date
- 2011-06-23
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT01379612
- Locations
- π©π°
Dept. of Oncology, Vejle Hospital, Vejle, Denmark
π©π°Dept. of Radiology, Vejle Hospital, Vejle, Denmark
Predictive Value of 18F-FAZA in Rectum Cancer
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT01257035
- Locations
- π©π°
Vejle Hospital, Vejle, Denmark
Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2010-11-17
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT01242449
- Locations
- π©π°
Dept. of Oncology, Aalborg Sygehus, Aalborg, Denmark
π©π°Department of Oncology, Vejle Hospital, Vejle, Denmark
π©π°Dept. of Oncology, Esbjerg Hospital, Esbjerg, Denmark
Molecular Screening for Lynch Syndrome in Southern Denmark
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2015-09-14
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT01216930
- Locations
- π©π°
Department of Pathology, Vejle, Denmark
π©π°Department of Clinical Genetics, Vejle, Denmark
π©π°Department of Pahology, Svendborg, Denmark
Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 88
- Registration Number
- NCT01206049
- Locations
- π©π°
Department of Oncology, Vejle Hospital, Vejle, Denmark
Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2010-04-23
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT01109615
- Locations
- π©π°
Vejle Hospital, Vejle, Denmark
Β© Copyright 2024. All Rights Reserved by MedPath